1 Min Read
April 20 (Reuters) - Gilead Sciences Inc
* Gilead sciences inc says presents data supporting efficacy and safety of vemlidy in patients with chronic hepatitis b after 96 weeks Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.